Development of in vivo gene therapy for sickle cell disease
Closed Pre-Solicitation Posted
- Solicitation number
- 75N92024Q1081
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
- More information
Notice details come from SAM.gov. Updated .
About this opportunity
Paragraph 1:
The Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute is seeking the development of an in vivo gene therapy for sickle cell disease. The procurement is classified under the NAICS code 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and the PSC code Q301 - Reference Laboratory Testing. The key objective is to develop an effective gene therapy to treat this debilitating blood disorder. Proposals will be evaluated based on the technical approach, qualifications of the research team, and the potential impact of the proposed solution. The pre-solicitation notice was posted on August 14, 2024, and responses are due by August 21, 2024.
Paragraph 2:
This procurement opportunity does not have any set-aside designations. No incumbent contractors are named in the notice. The potential award value or budget range is not specified. The notice does not provide any additional numerical details regarding the quantity of goods or timeline for services.
Notice text
Development of in vivo gene therapy for sickle cell disease
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity